24/7 Market News Snapshot 16 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 16, 2025

DENVER, Colo., 16 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN), an emerging player in RNA interference (RNAi) therapies targeting KRAS-driven cancers, witnessed a steep decline in its stock price today. Opening at $1.25, the stock plummeted to $0.932, marking a significant decrease of 40.26% from the previous close of $1.560. This notable drop in share value, alongside a trading volume of 4.84 million shares, suggests robust selling activity potentially linked to recent developments in the company’s pipeline or broader market conditions, prompting investors to closely observe future trading sessions for indications of recovery or continued decline.

Amid this challenging trading environment, Silexion announced promising preclinical results for its advanced siRNA candidate, SIL-204, designed to combat KRAS-driven pancreatic cancers. Recent data reveal substantial synergy between SIL-204 and leading chemotherapy options, such as 5-fluorouracil, irinotecan, and gemcitabine. In models featuring KRAS G12D mutations, SIL-204 demonstrated a significant enhancement in cancer cell reduction when combined with these established therapies, thus presenting a breakthrough potential in addressing the treatment of pancreatic cancer, which is notoriously difficult due to its prevalence of KRAS mutations.

Following the successful outcomes from its first-generation LODER™ platform during Phase 2 trials, Silexion’s strategy with SIL-204 aims to broaden treatment possibilities by targeting a wider array of KRAS mutations. The company is embarking on toxicology studies soon, with plans to initiate Phase 2/3 trials by 2026. Additionally, Silexion is preparing for a $5 million public offering to bolster its preclinical and clinical efforts, despite possible near-term dilution concerns.

As Silexion navigates the complexities of the market and clinical development, its advancements in RNAi technology position it as a pivotal innovator within the oncology landscape, striving to provide new therapeutic options for patients confronting KRAS-driven malignancies.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.